NCT03737240 trial results

Inclusion Criteria: * Type 2 diabetes, diagnosed for ≥ 6 months * HBA1c ≥ 9% - 15% * Previously treated with oral antidiabetic agents, including metformin, sulfonylurea, repaglinide/nateglinide, pioglitazone, dipeptidyl peptidase-4 (DPP4), inhibitors, SGLT2 inhibitors, (monotherapy + basal insulin) or in combination therapy (2-3 agents), and/or on basal insulin (neutral protamine hagedorn (NPH), detemir or glargine U100) at a total daily dose (TDD) 20-50 units (stable doses of metformin and basal insulin for at least 90 days, defined as up to ±10% variability) * Body mass index (BMI) ≤ 45 Kg/m2 Exclusion Criteria: * Subjects with type 1 diabetes or latent autoimmune diabetes of adults (LADA) (positive glutamic acid decarboxylase (GAD-65) antibody and/or ketones) * Subjects with a BG \> 400 mg/dL during the screening visit and laboratory evidence of diabetic ketoacidosis * Previous treatment with glucagon-like peptide-1 (GLP-1) agonists (during prior 3 months) * Previous treatment with basal-bolus insulin (within prior 3 months) * Recurrent severe hypoglycemia or known hypoglycemia unawareness. * Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia 2 * Patients with acute or chronic pancreatitis, pancreatic cancer * Patients with clinically significant hepatic disease (cirrhosis, jaundice, end-stage liver disease) or significantly impaired renal function (GFR \< 30 ml/min). * Treatment with oral or injectable corticosteroid (equivalent or higher than prednisone 5 mg/day), parenteral nutrition and immunosuppressive treatment. * Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study * Hypersensitivity to study drugs * Participating in another investigational drug trial * The receipt of any investigational drug (within 3 months) prior to this trial. * Previously randomized in this trial * Heart Failure New York Heart Association (NYHA) class 4 or uncontrolled hypertension (blood pressure \> 180/110 mmHg) * Female subjects who are pregnant or breast-feeding at time of enrollment into the study * Females of childbearing potential who are not using adequate contraceptive methods (as required by local law or practice) * Known or suspected allergy to trial medications (degludec, liraglutide, aspart), excipients, or related products. * Subjects could be excluded based on PI's discretion * Unable to comply with trial protocol, and/or at investigator discretion * Patients receiving treatment for active diabetic retinopathy or with proliferative retinopathy